Docetaxel in the treatment of prostate cancer: Opportunities for combination regimens and challenges to development

被引：0
|
作者：
Logothetis, CJ [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [21] Combination therapy for the treatment of multiple sclerosis: Challenges and opportunities
    Stuart, William H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1199 - 1208
  • [22] Biomarkers for prostate cancer: present challenges and future opportunities
    Sharma, Pranav
    Zargar-Shoshtari, Kamran
    Pow-Sang, Julio M.
    FUTURE SCIENCE OA, 2016, 2 (01):
  • [23] Challenges and Opportunities in Hormone-Resistant Prostate Cancer
    Miller, Kurt
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (01) : 36 - 45
  • [24] Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities
    Green, Michael
    Feng, Felix Y.
    Mehra, Rohit
    Spratt, Daniel E.
    IMMUNOTHERAPY, 2017, 9 (09) : 695 - 699
  • [25] Histone deacetylase inhibitor alone or in combination with docetaxel for the treatment of hormone-refractory prostate cancer cells
    Hwang, Jung Jin
    Kim, Yong-Sook
    Kim, Mi-Joung
    Lee, Je-Hwan
    Jang, Sejin
    Choi, Jene
    Ro, Seonggu
    Hyun, Young-Lan
    Cho, Joong Myung
    Kim, Choung-soo
    CANCER RESEARCH, 2009, 69
  • [26] Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines
    Epplen, Robin
    Stoeckle, Michael
    Engelmann, Udo
    Heidenreich, Axel
    Ohlmann, Carsten-Henning
    ACTA ONCOLOGICA, 2011, 50 (01) : 127 - 133
  • [27] A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer
    Moulder, S. L.
    Dhillon, N.
    Hong, D. S.
    Ng, C. S.
    Camacho, L. H.
    Hersh, E. M.
    Grenier, K. A.
    Boytim, M. L.
    Dorr, R. T.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer
    Nabholtz, JM
    North, S
    Smylie, M
    Mackey, J
    Au, HJ
    Au, R
    Morrish, D
    Salter, E
    Tonkin, K
    SEMINARS IN ONCOLOGY, 2000, 27 (02) : 11 - 18
  • [29] Docetaxel/trastuzumab combination therapy for the treatment of breast cancer
    Nabholtz, JM
    Gligorov, J
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (09) : 1555 - 1564
  • [30] Bisdemethoxycurcumin Augments Docetaxel Efficacy for Treatment of Prostate Cancer
    Song, Yanqin
    Ruan, Jian
    Liu, Shuxian
    Yu, Haizhou
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (08) : 1437 - 1446
12345